Welcome to our dedicated page for Inari Medical news (Ticker: NARI), a resource for investors and traders seeking the latest updates and insights on Inari Medical stock.
Inari Medical, Inc. (NASDAQ: NARI) is a medical device company focused on treating and transforming the lives of patients suffering from venous and other vascular diseases. This news page aggregates company announcements, clinical trial updates, financial disclosures, and event participation related to NARI stock.
Inari’s news often highlights developments around its thrombectomy technologies and venous interventions. The company has reported on clinical research programs such as the ClotTriever CLOUT Registry for deep vein thrombosis and randomized controlled trials including DEFIANCE and PEERLESS. For example, Inari announced positive PEERLESS results comparing its FlowTriever system to catheter-directed thrombolytics in intermediate-risk pulmonary embolism, with outcomes related to clinical deterioration, ICU use, hospital stay, and readmissions.
Investors and healthcare professionals can use this page to follow updates on regulatory and reimbursement milestones, such as national reimbursement approval in Japan for the ClotTriever Thrombectomy System for DVT and related distribution agreements. News items also cover international initiatives like Inari’s joint venture in Greater China with 6 Dimensions Capital, 120 Capital, and VFLO Medical to expand access to its technologies.
In addition, the feed includes information on Inari’s participation in major healthcare and investor conferences, including presentations at the J.P. Morgan Healthcare Conference, the Jefferies London Healthcare Conference, and analyst and investor meetings aligned with key clinical trial presentations. Financial news, such as quarterly results and guidance updates, is also featured. For ongoing insight into NARI’s clinical, commercial, and corporate developments, readers can consult this page as a centralized source of Inari Medical news.
Inari Medical, Inc. (NASDAQ: NARI), a medical device company focused on treating venous diseases, announced its participation in two upcoming investor conferences. The events include the 2020 Wells Fargo Virtual Healthcare Conference on September 10 at 10:00 a.m. ET and the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 16 at 5:00 p.m. ET. Interested parties can access a live and archived webcast through the Investor Relations section of Inari's website. The company specializes in developing minimally-invasive devices for thromboembolism treatment.
Inari Medical, Inc. (NASDAQ: NARI) will participate in the Canaccord Genuity 40th Annual Virtual Growth Conference, set for August 12 at 4:30 p.m. Eastern Time. Live and archived webcasts of the presentation will be available on their website. Inari focuses on treating venous diseases, specifically venous thromboembolism, using innovative catheter-based devices. The company’s FDA-cleared ClotTriever system addresses deep vein thrombosis, while the FlowTriever system is designed for pulmonary embolism treatment.
Inari Medical, Inc. (NASDAQ: NARI) will release its second quarter 2020 financial results after market close on August 11, 2020. A conference call and webcast discussing these results will occur at 1:30 PM PT. Interested parties can join via telephone or through Inari's website. Inari specializes in developing medical devices for treating venous diseases, focusing on innovative thrombectomy solutions, including the FDA-cleared ClotTriever and FlowTriever devices that safely remove blood clots without thrombolytic drugs.
Inari Medical, Inc. (NASDAQ: NARI) announced the successful closing of its initial public offering of 9,432,949 shares, with the underwriters exercising their option to purchase an additional 1,230,384 shares. The shares were priced at $19.00 each, yielding approximately $179.2 million in gross proceeds before expenses. The SEC declared the registration statement effective on May 21, 2020. Inari specializes in developing medical devices for treating venous diseases, particularly through its FDA-cleared ClotTriever and FlowTriever systems.
Inari Medical, Inc. (NASDAQ: NARI) has priced its upsized initial public offering of 8,202,565 shares at $19.00 per share, aiming for total gross proceeds of approximately $156 million. The offering, which begins trading on Nasdaq on May 22, 2020, includes a 30-day option for underwriters to purchase an additional 1,230,384 shares. This IPO will support Inari's focus on treating venous diseases through innovative medical devices. The offering is expected to close on May 27, 2020, contingent upon customary closing conditions.